Originally published In Press as doi:10.1074/jbc.M106164200 on March 28, 2002
J. Biol. Chem., Vol. 277, Issue 23, 20177-20184, June 7, 2002
Absence of Metabolic Cross-correction in Tay-Sachs Cells
IMPLICATIONS FOR GENE THERAPY*
Sabata
Martino
§,
Carla
Emiliani
,
Brunella
Tancini
,
Giovanni Maria
Severini¶,
Vanna
Chigorno
,
Claudio
Bordignon§,
Sandro
Sonnino
, and
Aldo
Orlacchio
**
From the
Dipartimento di Scienze Biochimiche e
Biotecnologie Molecolari, University of Perugia, 06126 Perugia, Italy,
§ San Raffaele Telethon Institute for Gene Therapy, H. S. Raffaele, Milano, Italy, ¶ Children Hospital "Burlo Garofolo,"
34100 Trieste, Italy, and the
Department of Medical Chemistry
and Biochemistry, Center of Excellence on Neurodegenerative Diseases,
Study Center for the Biochemistry and Biotechnology of Glycolipids,
University of Milan, 20090 Segrate, Italy
Received for publication, July 2, 2001, and in revised form, March 28, 2002
 |
ABSTRACT |
We have investigated the ability of a
receptor-mediated gene transfer strategy (cross-correction) to restore
ganglioside metabolism in fibroblasts from Tay-Sachs (TS) patients
in vitro. TS disease is a GM2 gangliosidosis attributed to
the deficiency of the lysosomal enzyme
-hexosaminidase A (HexA)
(
-N-acetylhexosaminidase, EC 3.2.1.52). The hypothesis
is that transduced cells overexpressing and secreting large amounts of
the enzyme would lead to a measurable activity in defective cells via a
secretion-recapture mechanism. We transduced NIH3T3 murine fibroblasts
with the L
HexTN retroviral vector carrying the cDNA encoding for
the human Hex
-subunit. The Hex activity in the medium from
transduced cells was approximately 10-fold higher (up to 75 milliunits)
than observed in non-transduced cells. TS cells were cultured for
72 h in the presence of the cell medium derived from the
transduced NIH3T3 cells, and they were analyzed for the presence and
catalytic activity of the enzyme. Although TS cells were able to
efficiently uptake a large amount of the soluble enzyme, the
enzyme failed to reach the lysosomes in a sufficient quantity to
hydrolyze the GM2 ganglioside to GM3 ganglioside. Thus, our results
showed that delivery of the therapeutic HexA was not sufficient to
correct the phenotype of TS cells.
 |
INTRODUCTION |
Tay-Sachs (TS)1 disease
is a GM2 gangliosidosis attributed to the deficiency of the lysosomal
enzyme
-hexosaminidase A (HexA) (
-N-acetylhexosaminidase, EC 3.2.1.52). HexA is a
heterodimer of an
- and
-subunits encoded by two different genes,
HEXA and HEXB, located on chromosomes 15 and 5, respectively. Inherited defects in the
-subunit gene lead to
the absence of the HexA and a massive accumulation of the GM2
ganglioside and related lipids primarily in neuronal lysosomes.
Consequences are a severe cellular dysfunction and a rapid progressive
neurodegeneration (1-3).
In human and other mammalian tissues,
-hexosaminidase exists in two
major forms, HexA (
structure) and HexB (
structure) (1).
Minor forms of Hex have also been described and characterized (4-6).
The homodimer 
, HexS, represents the residual Hex activity in
Sandhoff disease patients, a type 0 GM2 gangliosidosis attributed to
inherited defects in the HEXB gene, and predominates in the presence of an altered balance between the
- and
-subunits
(i.e. in leukemic cells) (7-10). Recently, Sandhoff and
co-workers (11) demonstrated that this form has catalytic activity such
as HexA toward anionic glycolipids, anionic glycans, and neutral
N-glycans.
The formation of the HexA is controlled by a complex mechanism that
ultimately results in the association of the
- and
-subunits (1-2, 12, 13). This event requires the transport of both subunits to
the Golgi apparatus compartment and regulation of the ratio between
them. In the Golgi apparatus, a second important event occurs, the
generation of the mannose-6-phosphate recognition marker. As result of
this modification, the mannose-6-phosphate receptor recognizes and
targets the enzyme to the lysosomes. The enzyme is then subjected to a
final proteolytic processing, and in the presence of the GM2 activator
protein, the enzyme hydrolyzes the
-GalNAc-(1-4)-
-galactosidase
glycosidic linkage (1, 8, 11, 14-15).
No effective treatment is currently available for TS disease. Gene
therapy holds the greatest promise for genetic diseases in which single
gene mutations are responsible for the metabolic alterations.
Vector-mediated gene transfer (direct correction) or receptor-mediated
gene transfer (cross-correction) represent two potential approaches for
lysosomal storage disorders (16-18). The first transfer is based on
the introduction of the missing gene to the deficient cells. In this
case, the deficient cells produce the lacking enzyme. The second
transfer is based on the rationale that secreted lysosomal enzymes can
be uptaken by the neighboring cells through the binding with plasma
membrane mannose-6-phosphate receptor.
In this paper, we have focused on the understanding of the mechanisms
leading the effectiveness of the cross-correction strategy using human
TS cells as a model. Moreover, because the combination of the two
approaches is requested for the diffusion of the therapeutic enzyme and
for the success of the gene transfer treatment in the patients
(i.e. bone marrow gene transfer, local gene transfer delivery) (19-22), we have compared the efficacy of both approaches to
restore the HexA activity in TS cells.
We first transduced human fibroblasts from TS patients with a
retroviral vector carrying the cDNA encoding for the human Hex
-subunit and defined the ability of the recombinant HexA to restore the GM2 ganglioside metabolism. Second, we have cross-corrected human
TS fibroblasts by using the HexA secreted either by transduced murine
fibroblasts or by human-transduced TS cells and investigated the
efficiency of this mechanism.
All of our results demonstrate that although both strategies were able
to give rise to adequate levels of the missing enzyme in the deficient
cells, the GM2 metabolism was only restored in transduced TS cells.
 |
EXPERIMENTAL PROCEDURES |
Materials--
The GM2 activator protein was kindly
provided by Professor Yu-Teh Li (Tulane University, New Orleans, LA).
The fluorogenic substrates such as the 4-methylumbelliferyl derivative
of
-N-acetylglucosaminide (MUG),
-N-acetylglucosamine-6-sulfate (MUGS),
-D-galactosidase, and
-D-mannopyranoside and 4-methylumbelliferone,
Nonidet P-40, agarose gel for electrophoresis, and mannose-6-phosphate
were from Sigma. Bovine serum albumin and protein assay reagent
were from Bio-Rad, and DE52 DEAE-cellulose was from Whatman
Biochemicals. The medium for tissue culture was from Euro-Clone (Celbio
Laboratories), the fetal calf serum and Colorado serum were from Mascia
Brunelli, penicillin/streptomycin was from Invitrogen, and
Gentamicin (G418), Polybrene, and restriction enzymes were from Roche
Molecular Biochemicals. Centriprep 30 was from Amicon. All other
reagents were of analytical grade.
Cell Cultures--
Human fibroblasts established from three
patients with the late infantile form of TS disease were kindly
provided by the Laboratorio di Diagnosi Pre/Post-natale Malattie
Metaboliche, Istituto G. Gaslini Hospital (Genova, Italy). Normal human
fibroblasts are routinely used in our laboratory (23). Fibroblasts were
cultured in EMEM containing 10% (v/v) heat-inactivated fetal calf
serum in 25-cm2 culture flasks in a humidified atmosphere
containing 5% CO2 at 37 °C. NIH3T3 mouse fibroblasts
were cultured in DMEM containing 10% (v/v) heat-inactivated Colorado
serum in 25-cm2 culture flasks in the same conditions as
described above. Cell growth was determined by counting cells in a
hemocytometer. The viability of the cells was estimated by examining
their ability to exclude trypan blue (0.1% in 0.9% NaCl).
At confluence, cells were trypsinized and harvested by centrifugation
(1000 rpm for 10 min in a bench top centrifuge). After two washings with 0.9% NaCl, the pellet was resuspended in 10 mM sodium phosphate buffer, pH 6.0, containing 0.1% (v/v)
Nonidet P-40 detergent and sonicated. The lysates were centrifuged at 12,000 rpm in a Eppendorf Microfuge for 20 min, and the supernatants were used as cell extracts for enzyme analysis. All procedures were
carried out at 4 °C.
Construction of a Suitable Retroviral Vector for Hex
-Subunit
cDNA Transfer and Transduction--
We cloned the cDNA
encoding for
-subunit of human HexA (ATCC, Manassas, VA) into the
Moloney leukemia virus retroviral vector backbone LXTN. In this
vector, the cDNA is under the long terminal repeat promoter.
This vector contained also the neomycin resistance gene. The
tk-neo fusion gene is under the control of the tk
promoter (24). The procedure for the production of the retrovirus was as follows. The E86 ecotropic packaging cell line was transfected with
the vector carrying the
-subunit cDNA by standard calcium phosphate co-precipitation. The E86 supernatants were collected, filtered (diameter 0.45 µm), and used to infect the
amphotropic packaging cell lines AM12 in the presence of polybrene.
After selection with neomycin (G418), the best AM12-transduced clone, was selected by titration and used as viral producer packaging cells.
Viral supernatants were collected, filtered through 0.45-µm pore size
filters, and used to infect the designed cells. One day before the
infection, TS cells were plated at 75% confluence. The following day,
cells were incubated with viral supernatant in the presence of
polybrene for 16 h at 37 °C. After G418 selection, the
transduced cells were analyzed for the
-subunit gene expression and
for the HexA properties. The same procedure was used to transduce murine fibroblasts NIH3T3.
Administration of the HexA to TS Cells--
Human TS cells were
cultured in the medium (conditioned medium) containing HexA secreted by
transduced NIH3T3 cells for 72 h in 25-cm2 culture
flasks at 37 °C. The total enzyme activity in the conditioned medium
was up to 75 milliunits. The medium was changed every 24 h for 3 days. Untreated and treated TS cells were harvested and evaluated for
the HexA properties. As experimental control, TS cells were cultured in
conditioned medium containing different amounts of HexA secreted either
by transduced TS cells or normal fibroblasts.
In some experiments, mannose-6-phosphate was added to the conditioned
medium to have a 5 mM final concentration. These cells were
then analyzed for hexosaminidase, galactosidase, and mannosidase activities.
-Hexosaminidase Activity Assay--
Enzyme activity was
determined by using the two fluorogenic substrates, 3 mM
MUG or MUGS in 0.1 M citrate/0.2 M disodium
phosphate buffer, pH 4.5 (25). Fluorescence of the liberated
4-methylumbelliferone was measured on a PerkinElmer LS3 fluorometer
(excitation 360 nm, emission 446 nm).
The optimum pH for the HexA activity was determined by testing the
enzyme activity in citrate/sodium phosphate buffers in the pH range of
3.5-7.5 (5). To define the thermal stability, 50 µl of each sample
were incubated at 52 °C for different times, cooled on ice for
1 h, and then assayed at 37 °C for the Hex activity. The
results represented the average of at least three independent experiments and are expressed as a percentage of the activity found in
the controls kept on ice (5). The inhibitory effect of glucosamine
toward the HexA was by incubating Hex isoenzymes at 37 °C in the
presence of 100 mM glucosamine. The results are the average
of at least three independent experiments and are expressed as a
percentage of the activity of treated samples with respect to untreated
control (25).
-Hexosaminidase Isoenzymes Analysis--
Cell lysates were
analyzed by the ion-exchange chromatography on DEAE-cellulose (25). The
chromatography was performed by using 1-ml column equilibrated with 10 mM sodium phosphate buffer, pH 6.0 (buffer A). The flow
rate was 0.5 ml/min. Enzyme activity retained by the column was eluted
by a linear gradient of NaCl (0.0-0.5 M in 40 ml of buffer
A). Finally, the column was eluted with 1.0 M NaCl in the
same buffer. Fractions (1 ml) were collected and assayed for the Hex
activity with the two substrates, MUG and MUGS.
Subcellular Fractionation--
Cells at confluence were
harvested and resuspended in 0.25 M sucrose and then
homogenized in a Potter Elveheim-type homogenizer until >90% of the
cells were disrupted. Differential centrifugation of the homogenate was
performed at 800 × g for 10 min at 4 °C in the AJ20
rotor of a Beckman J2-21 centrifuge to sediment the nuclear fraction.
The supernatant was then centrifuged at 13,000 × g for
15 min to sediment the lysosomal fraction, and the supernatant (post-lysosomal fraction) from this step was decanted (25).
Preparation of Radioactive Gangliosides GM1 and
GM2--
Gangliosides GM1 and GM2 were extracted from calf brain (26)
and purified to 99% by silica gel-ion exchange, dialysis, and precipitation from acetone. Their structural and homogeneity
characterization was performed as described elsewhere (27, 28).
[3H]GM1 and [3H]GM2 containing
erythro-C18-sphingosine isotopically tritium-labeled at
position 3 were prepared from GM1 and GM2 by the
dichloro-dicyano-benzoquinone/sodium boro-[3H]hydride
method followed by reversed-phase high pressure liquid chromatography
purification (26, 29) (homogeneity over 99%, specific radioactivity of
1.2 and 1.3 Ci/mmol, respectively). Radioactive standard gangliosides
and sphingolipids are available in the laboratory (30).
Feeding Experiments--
[3H]GM1 or
[3H]GM2, dissolved in propan-1-ol/water (7:3 by volume)
were pipetted into a sterile tube and dried under a nitrogen stream.
The residue was solubilized in an appropriate volume of pre-warmed
(37 °C) EMEM to obtain a ganglioside concentration of 5 × 10
7 M. After the removal of the original
medium and rapid washing of cells with EMEM, 2 ml of the medium
containing the radioactive lipid were added to each 60-mm dish, and the
cells (TS fibroblasts, normal fibroblasts, transduced TS fibroblasts,
cross-correct TS fibroblasts) were incubated for 3 h at 37 °C.
After incubation, the radioactive medium was removed, and the dishes
were washed first with EMEM solution for 5 min and then with 10% fetal
calf serum-EMEM for 30 min. After a chase of 15 h, cells were
washed twice with phosphate-buffered saline, scraped off with a rubber policeman, and centrifuged at 1000 × g for 10 min. The pelleted cells were subjected to lipid extraction (27)
resulting in a delipidized pellet and a total lipid mixture. The
radioactivity imaging of thin layer chromatography plates of lipid
extracts was acquired with a
-imager 2000 instrument (Biospace,
Paris, France). The radioactivity associated with individual lipids was determined with the specific
-vision software provided by the manufacturer (Biospace), and the radioactivity associated with total
lipid extracts was determined by liquid scintillation counting (30).
Degradation of GM2 by Secreted HexA--
Transduced confluent
NIH3T3 cells were maintained in culture for 72 h in the presence
of the 10 mM NH4Cl, which specifically increases all secreted lysosomal enzyme activities (31). The medium was
collected and partially purified by ion-exchange chromatography on
DEAE-cellulose as described above. The assay was performed using 50 milliunits of secreted HexA toward MUG in 170 µl of 10 mM, pH 4.5, citrate buffer containing 10 µg of GM2
activator protein, 0.1% bovine albumin, 52 µg of sodium
taurodeoxycholate, and 20,000 dpm of GM2 (3 µg). The enzyme reaction
mixture was maintained at 36 °C under continuous vortexing for
12 h. The reaction mixture was mixed with three volumes of
tetrahydrofuran, the mixture was centrifuged, the clear solution was
dried, and the residue was resuspended into a few microliters of
chloroform/methanol 2:1 by volume. The solutions were analyzed by high
performance thin layer chromatography followed by radioimaging
and quantitative detection of the separated GM2 and GM3.
Other Analytical Methods--
Proteins were measured by the
method of Bradford (32) using the serum bovine albumin as standard.
Lipids were analyzed by chromatography on silica gel on high
performance thin layer chromatography plates (Merck) using the
solvent system chloroform/methanol/0.2% aqueous CaCl2
(50:42:11 by volume) in comparison with standard compounds followed by
radioactivity imaging (28).
 |
RESULTS |
Construction of a Retroviral Vector for Hex
-Subunit
cDNA--
The recombinant retrovirus based on a Moloney murine
leukemia virus backbone LXTN vector containing the wild-type Hex
-subunit cDNA was produced (Fig.
1). In this vector, the
-subunit
cDNA is expressed under the control of the promoter/enhancer
sequence in the viral long terminal repeat; the
tk-neo fusion gene is under the control of the tk promoter.
The HSV-tk gene is contained in the vector as a safety
mechanism (24). The L
HexTN is used to produce the L
HexTN
recombinant retrovirus and transduce human fibroblasts from TS patients
and NIH3T3 cells as described under "Experimental Procedures." The
presence of Hex
-subunit cDNA in the retroviral-transduced cells
was evaluated by Southern blot analysis (data not shown).

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 1.
Recombinant retrovirus containing
-Hex cDNA. The recombinant retrovirus was
produced as described under "Experimental Procedures." -Hex
cDNA is expressed under the promoter/enhancer sequence in the viral
long terminal repeat. The tk-neo is under the control of the tk
promoter.
|
|
Vector-mediated Gene Transfer Strategy for TS Cells--
After
selection with G418, transduced TS cells display a Hex-specific
activity of 4.2 ± 0.8 milliunits/mg as evaluated with the
fluorogenic substrate MUGS, which is hydrolyzed only by the
-subunit
(33). This value is comparable with that measured in control
fibroblasts (Fig. 2A). The
secreted HexA activity in the culture medium of transduced TS cells was
comparable with that of normal fibroblasts and was much higher with
respect to TS cells (Fig. 2B).

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 2.
HexA activity in cells transduced with the
vector expressing -Hex cDNA. The
intracellular (A) and the secreted (B) Hex
activity was assayed toward the synthetic substrate MUGS. One unit is
the amount of enzyme that hydrolyses 1 µmol/min substrate at
37 °C. NF, normal fibroblasts; t-TS,
transduced TS; t-NIH3T3, transduced NIH3T3;
NIH3T3, non-transduced NIH3T3.
|
|
The isoenzyme pattern of Hex in transduced TS cells has been determined
by ion-exchange chromatography on DEAE-cellulose (25). Under our
experimental conditions, HexB was unretained by the column and eluted
with void volume, whereas HexA or other minor forms (HexS or Hex
intermediate forms) was eluted by a linear gradient of NaCl (0.0-0.5
M in buffer A). Besides, the combination of the
chromatographic analysis and the specific enzymatic assay with the two
substrates, MUG, which is hydrolyzed by both
- and
-subunits, and
MUGS, which is hydrolyzed only by
-subunit, provides information
about the subunit composition of the Hex isoenzymes. In
L
HexTN-transduced human TS cells, the Hex activity was composed of
HexA and HexB with a Hex isoenzyme pattern similar to that of control
cells (Fig. 3, b and
c). No presence of HexS was detected. On the contrary, TS
cells were characterized by the complete absence of HexA. They have
HexB and a second enzyme form eluted by the gradient at the NaCl
concentration required to elute the intermediate forms of Hex (HexI)
(5). The 
structure of this form was demonstrated by its
inability to hydrolyze the MUGS substrate (Fig. 3a).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 3.
DEAE-cellulose chromatography analysis of
HexA in transduced cells. a, Tay-Sachs cells.
b, transduced TS cells (t-TS). c,
normal fibroblasts (NF). d, non-transduced
NIH3T3-secreted activity, e, transduced NIH3T3
(t-NIH3T3)-secreted activity. Similar amounts of protein for
each sample was loaded into a 1-ml column equilibrated with 10 mM sodium phosphate buffer, pH 6.0. After loading, the
column was eluted at 15 ml with 10 mM sodium phosphate
buffer, pH 6.0. HexA activity retained by the column was eluted with 40 ml of a linear gradient of NaCl (0-0.5 M in the above
buffer). Fractions (1 ml) were collected and assayed for Hex activity
toward the two substrates MUG ( ) and MUGS ( ).
|
|
Recombinant HexA from transduced TS cells and HexA from control
non-transduced cells were separated from the other isoenzymes by
preparative DEAE-cellulose chromatography and analyzed for their
biochemical properties (5, 25, 34). They showed the same optimum pH of
4.5 toward both MUG and MUGS substrates (data not shown) and displayed
comparable curves of heat inactivation when incubated at 52 °C for
different intervals of time with almost complete inactivation after 15 min (Fig. 4A). In the presence of 100 mM glucosamine (the specific inhibitor of the
-subunit), HexA (
dimer) from transduced and control cells
lost approximately 50% of its original activity (Fig. 4B).
As internal control, the effect of glucosamine was also tested on Hex B
(
dimer) isolated either from control cells or from transduced TS
cells and on HexS (
dimer obtained from HL60 cell line, see Ref.
9). HexB lost ~80% of its original activity in agreement with
previous data (25), whereas HexS was activated.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 4.
HexA biochemical properties. HexA from
transduced human TS cells ( ) and from control cells ( ) displayed
a comparable behavior of heat inactivation when incubated at 52 °C
for different intervals of time with almost complete inactivation after
15 min (A). In the presence of 100 mM
glucosamine, HexA from transduced and control cells lost ~50% of its
activity (B). Results are the means ± S.D. of three
different experiments.
|
|
GM2 Ganglioside Hydrolysis in Transduced Human TS Cells--
Fig.
5 shows the radioactive lipid pattern of
transduced cells fed with [3H]GM1. Radioactive
ganglioside was taken up by the cells and catabolyzed to GM2
GM3
neutral sphingolipids with a hydrolysis rate comparable with that
of control cells, demonstrating the restoration of the metabolic defect
in transduced TS cells.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 5.
Radioactive lipid pattern from transduced
cells fed with [3H]GM1. The total cell lipid extract
was separated by high performance thin layer chromatography
using the solvent system chloroform/methanol/0.2% aqueous
CaCl2 (50:42:11 by volume). Radioactive lipids were
detected by digital autoradiography. 200-400 dpm were applied on a
4-mm line. Time of acquisition was 24 h. Lane a,
standard GM1; lane b, normal fibroblasts;
lane c, TS fibroblasts; lane d, transduced TS
fibroblasts; lane e, standard GM2; lane f,
standard GM3.
|
|
Production of a Suitable Enzyme Producer Cell Lines--
After
transduction with the retroviral vector L
HexTN, HexA was
overexpressed in NIH3T3 cells. An increase of ~10-folds of the cell
enzyme activity toward the substrate MUGS was observed (Fig.
2A). Furthermore, transduced NIH3T3 cells released high levels of Hex activity in the medium of culture (Fig. 2B).
No atypical intracellular Hex isoenzymes such as HexS were detected by
DEAE-cellulose chromatography in transduced NIH3T3 cells, but an
increase of the HexB activity was observed (data not shown). These data
were confirmed by ion-exchange chromatography analysis of secreted Hex
activity of both transduced and non-transduced cells. Fig. 3,
d and e, show a successful production of high
levels of the secreted HexA, which before eluted ~10 ml of the
intracellular HexA activity. The amount of the enzyme secreted into the
medium of culture was in the proportion to the cell number.
As control, NIH3T3 cells were also transduced with a similar retroviral
vector carrying as report gene the cDNA encoding for the enzyme
-galactosidase. There were no changes in the intracellular or in the
secreted Hex activity in transduced cells; no increase of HexB activity
was revealed by DEAE-cellulose chromatography (data not shown).
Hex isoenzymes secreted by transduced NIH3T3 cells were partially
purified by preparative DEAE-cellulose chromatography and were
analyzed for their biochemical properties as described above. The
curves of heat inactivation, the assay in the presence of 100 mM glucosamine, and the chromatographic pattern itself
confirmed that the released Hex activity corresponds to HexB and HexA
with the total absence of HexS (data not shown).
The ability of the HexA secreted by transduced NIH3T3 cells to
hydrolyze the natural ganglioside GM2 was determined in an in
vitro assay in the presence of GM2 activator protein. The
retroviral-transduced NIH3T3 cells were maintained in culture for
72 h, and then the secreted HexA was separated from the other
protein of the culture medium by DEAE-cellulose chromatography. The
enzyme activity on the natural substrate GM2 ganglioside was tested
(31). Although the enzyme activity was low (Fig.
6), the measured hydrolysis rate was
comparable with that determined for the enzyme secreted from normal
human fibroblasts.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 6.
Degradation of GM2 ganglioside by HexA
secreted in to the culture medium by retroviral-transduced NIH3T3
cells. The assay was performed in the presence of the GM2
activator protein.
|
|
Receptor-mediated Gene Transfer Strategy for TS Cells--
TS
cells from three patients were incubated for 72 h with the medium
from L
HexTN-transduced NHI3T3. The conditioned medium was changed
every 24 h. After 72 h, cells were harvested, and the HexA
activity was evaluated. The cross-correction procedure was able to
restore the Hex activity toward MUGS substrate in all TS fibroblasts
from patients considered in this study (Fig. 7A). The internalization of
the HexA was time-dependent, the maximum uptake of the
enzyme occurring after 72 h of incubation. Fig. 7B shows the Hex isoenzyme pattern in TS cross-corrected
cells and demonstrates the presence of HexA uptake. This enzyme
displayed optimum pH of 4.5 versus both MUG and MUGS
substrates and a curve of heat inactivation when incubated at 52 °C
for different intervals of time comparable with that of the control
enzyme (data not shown).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 7.
HexA activity in cross-corrected TS
fibroblasts. Enzyme activity was evaluated using the substrate
MUGS. A, TS cells were incubated in conditioned medium
containing 75 milliunits of HexA secreted by transduced NIH3T3 for
72 h. The conditioned medium was changed every 24 h to
maintain constant concentration of fresh HexA. In some experiments,
confluent TS cells were grown for 4 days in conditioned medium
containing 5 mM mannose-6-phosphate (M6P);
cc-TS, cross-corrected TS; cc-TS+M6P, TS cells
cross-corrected in the presence of M6P. B, ion-exchange
chromatography pattern of HexA from cc-TS.
|
|
When cross-correction experiments were performed in the presence of 5 mM mannose-6-phosphate, no HexA activity could be recorded in TS cells (Fig. 7A). This finding suggests that the uptake
process of HexA by TS cells occurs through the mannose-6-phosphate
surface receptor mechanism. Cross-corrected TS cells exhibiting a
MUGS-specific activity of 4.5-4.8 milliunits/mg cell protein were fed
with radioactive gangliosides GM2 or GM1. Fig.
8 shows that in cross-corrected TS cells,
the hydrolysis of GM2 to GM3 does not occur. GM2 ganglioside was taken
up by the cells but was not catabolyzed (Fig. 8, lanes e-i), whereas GM1 ganglioside was taken up by the cells and
hydrolyzed to GM2 that was not further processed but was stored (Fig.
8, lanes e-i). Identical results were obtained when TS
cells were cross-corrected with HexA secreted either by
L
HexTN-transduced human TS cells or by control human fibroblasts. In
these experimental conditions in TS cells, the internalized MUGS
activity was 22.7 and 14.5%, respectively, with respect to the normal
fibroblasts (Fig. 9). In both cases, the
MUGS uptake activity was lower than that observed in cross-corrected TS
cells with HexA secreted by transduced NIH3T3, but this value was in
the range of the activity required to correct the phenotype (1). The
lower enzyme activity is not surprising considering that the enzyme
activity in the cell medium collected from normal cells and transduced
TS cells was ~20 times lower than that present in the medium
collected from NHI3T3-transduced cells (Fig. 2B). Therefore,
these cross-corrected TS cells were fed with radioactive GM1
ganglioside as previously described, but again the HexA taken up by the
cells was not able to hydrolyze the GM2 ganglioside to GM3
ganglioside (Fig. 8, lane l). The same results were also
obtained by using a 10× conditioned medium containing HexA secreted
either by L
HexTN-transduced human TS cells or by control human
fibroblasts (Fig. 9) where the percent of internalized activity was
significantly increased. Thus, the absence of hydrolysis was not
related to the amount of HexA taken up by the cells (data not
shown).

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 8.
Radioactive lipid pattern of cross-corrected
cells fed with [3H]GM2 and [3H]GM1.
The total cell lipid extract was separated by high performance thin
layer chromatography using the solvent system
chloroform/methanol/0.2% aqueous CaCl2 (50:42:11 by
volume). Radioactive lipids were detected by digital autoradiography.
200-400 dpm were applied on a 4-mm line. Time of acquisition was
24 h. Lane a, standard lactosylceramide; lane
b, standard GM1; lanes c, standard GM2; lanes
d, standard GM3; lanes e, normal fibroblasts;
lanes f and h, TS cells (patients 1 and 2);
lanes g and i, TS cells cross-corrected with the
conditioning medium from transfected NIH3T3 cells (patients 1 and 2);
lane l, TS cells cross-corrected with the conditioning
medium from transduced TS cells; lane m, mixture of
radioactive standard gangliosides.
|
|

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 9.
Percentage of MUGS activity in
cross-corrected TS cells. TS cells were incubated in conditioned
medium containing HexA secreted by transduced TS (t-TS)
cells or secreted by normal fibroblasts (NF) in the same
condition described in the legend for Fig. 6. In the same experiment,
TS cells were incubated in 10× concentrated conditioned medium
containing HexA secreted by transduced TS (t-TS) cells or
secreted by NF. Enzyme activity was evaluated using the substrate
MUGS.
|
|
These findings suggest that the enzyme taken up by the cells could not
be transported to the lysosomes where the hydrolysis of natural
substrate process occurs. This aspect was further investigated. The
nuclear, lysosomal, and post-lysosomal fractions were obtained by the
differential centrifugation. The lysosomal fraction of cross-corrected
cells had MUGS activity (Fig. 10) that
was approximately one-tenth of that associated with the normal
fibroblast lysosomal fraction. These data suggest that the amount of
the lysosomal HexA requested to prevent the metabolic phenotype (1) may
be inadequate to hydrolyze the GM2 when affected lysosomes are
considered.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 10.
Subcellular fractionation of cross-corrected
TS cells. Subcellular fractionation of cross-corrected TS cells
(ccTS), TS cells, and normal fibroblasts (NF).
The nuclear (N), lysosomal (L), and
post-lysosomal (PL) fractions were obtained by differential
centrifugation (25). Results are expressed as relative specific
activity (RSA). In this figure, the distribution of the
activities of other lysosomal enzymes ( -mannosidase and
-galactosidase) as experimental control also is reported. RSA is the
ratio of the percentage of the activity of each fractions and the
percentage of the proteins in that fraction.
|
|
 |
DISCUSSION |
The restoration of the metabolic defect in human Tay-Sachs cells
has been evaluated by the receptor-mediated gene transfer strategy
(cross-correction). This strategy is based on the rationale that part
of each lysosomal enzyme is secreted and can be uptaken by the
neighboring cells via the mannose-6-phosphate receptor (35-37). The
hypothesis is that transduced cells overexpressing and secreting large
amounts of these enzymes would lead to a measurable activity in
defective cells via secretion-recapture mechanism.
We explored cross-correction by using an in vitro model.
Human TS fibroblasts were incubated in HexA-containing medium and were
evaluated for HexA properties, localization, and activity on
radioactive natural compounds previously fed to the cells. To mimic the
gene transfer procedures in the clinic, we have used as enzyme producer
cells transduced with a Moloney murine leukemia virus retroviral vector
carrying the cDNA encoding for the human
-subunit of the HexA,
L
HexTN (Fig. 1). The efficacy of the vector to restore the enzyme
activity within the TS cell on natural compounds was demonstrated by
the transduction of human TS fibroblasts (Fig. 5). In this context, it
is known that a correct
- and
-subunit association is required
(2, 11). A combination of the DEAE-cellulose chromatography and the
enzyme assay with the two fluorogenic artificial substrates, MUGS,
which is hydrolyzed only by Hex isoenzymes containing
-subunit, and
MUG, which is hydrolyzed by Hex isoenzymes containing
- and/or
-subunit, was used to verify the correct HexA formation (Fig. 3,
a-c). L
HexTN-transduced human TS fibroblasts had HexA activity and properties (optimum pH, thermal stability behavior, and
similar sensibility to the glucosamine) similar to that of control
cells (Fig. 4).
The HexA activity on natural compounds in the transduced TS cells was
evaluated by cell-feeding experiments with radioactive gangliosides. In
both TS (Fig. 5, lane c) and transduced TS cells (Fig. 5,
lane d), the exogenous [H3]GM1 reached the
lysosomes where it was correctly converted by the galactosidase to GM2
ganglioside. Only in transduced TS cells, the GM2 ganglioside was
hydrolyzed to GM3 ganglioside and neutral sphingolipids. Because the
GM2 ganglioside hydrolysis requires a concerted action between both the
/
-subunits of HexA and the small GM2 activator protein (1), this
hydrolysis confirms the correct structure of the recombinant enzyme.
Thus, the detection of the GM3 ganglioside in transduced TS cells
demonstrates the restoration of the metabolic defect.
We have used the murine cell lines NIH3T3 transduced with the
retroviral vector L
-HexTN as enzyme producer cells to overexpress HexA. Many authors (38) have used these cells in similar experiments. Transduced NIH3T3 released high levels of HexA activity into the culture medium. Unexpectedly, we also observed an increase in HexB
levels in transduced cells in comparison with the non-transduced cell
lines. Because NIH3T3 cells constitutively express the
-subunit, its
overexpression could negatively influence the stoichiometric process of
- and
-subunit association and lead to the formation of HexS
(
dimer) (9, 25, 39). However, in our experimental conditions,
the
- and
-subunit balance was naturally resolved; in fact no
HexS was detected. Moreover, we are investigating whether the increase
in
-subunit level is related to the
-subunit overexpression. Lacorazza et al. (40) showed similar findings in C17
neuroblastoma clone transduced with a different retroviral vector
expressing the
-subunit gene.
To perform the cross-correction experiments, the medium containing HexA
secreted by transduced NIH3T3 was used to culture TS cells. Culture
media with different amounts of Hex activity were used. TS cells uptake
HexA from the medium of culture (Fig. 7) by a mannose-6-phosphate
receptor-dependent mechanism (Fig. 7A). The
level of HexA activity restored in TS cells was comparable with that
measured in control human fibroblasts (Figs. 2A and Fig.
7A). Nevertheless, the HexA uptake could not catabolyze GM2 ganglioside (Fig. 8). Identical findings were obtained by culturing TS
cells in medium containing different amounts of enzyme activity (1×
versus 10×) secreted either by human-transduced TS cells or human normal fibroblasts. In this context, we observed that the MUGS
activity internalized in TS cells was lower when compared with the
activity measured in cross-corrected TS cells with the medium
containing HexA secreted by transduced NIH3T3, but it was sufficient to
give rise to the normal phenotype (1). We may address the observed
discrepancy on the amount of the internalized MUGS activity to the
higher level of the HexA released by transduced NIH3T3 cells in the
medium of culture with respect to HexA released by normal fibroblasts.
However, all of these data indicate that the chimerical structure of
the internalized enzyme (human - the exogenous
-subunit - and
mouse - the endogenous
-subunit) is not responsible for the missing
GM2 ganglioside hydrolysis. Therefore, it is well known that the murine
and human
-subunit cDNAs have very high homology of >80% (41,
42)
Moreover, the HexA secreted by transduced NIH3T3 hydrolyzes as does the
enzyme secreted by normal human fibroblasts, GM2 to GM3 ganglioside.
All together, these data suggest that the structure of the recombinant
enzyme is not responsible for the missing GM2 ganglioside hydrolysis,
and that most probably the enzyme does not localize into the lysosomes.
To clarify these findings, we evaluated the localization of HexA in
cross-corrected TS cells. Subcellular fractionation of cross-corrected
TS cells showed an atypical pattern of enzyme distribution with
unexpectedly high levels of MUGS activity in all subcellular fractions.
Thus, only a minor part of the cell-restored activity was associated to
the lysosomes. Although this activity, if all belonging to the inner
volume of lysosomes, should be sufficient to restore the GM2
ganglioside metabolism (1), it probably may be inadequate to hydrolyze
the GM2 when affected lysosomes are considered. Moreover, we cannot
conclude that the enzyme associates to the lysosome membranes
but does not belong to the lysosomes.
In addition, the storage of lipids in the lysosomes may change membrane
trafficking along the lysosomal pathway (43). In this regard, Kabayashi
et al. (44) have shown that lysobisphosphatidic acid
is localized to the late endosomes and may have an important role in
the protein-sorting functions of endosomes. In particular, they show
that the lysobisphosphatidic acid is the main component of the endosome
membrane domains, and that these specialized domains are involved in
sorting the multifactor receptor for insulin-like growth factor 2 and
ligands bearing mannose-6-phosphate, particularly lysosomal enzymes
(45). Thus, the mannose-6-phoshate mechanism may be not sufficient to
target the enzyme to the lysosomes.
Alternatively, the membrane fluidity of the endosomes may be altered in
the mutant cells, resulting in an abnormal lipid/protein trafficking
(38). An abnormal transport along the lysosomal pathway has been
described in the mucolipidosis type IV disease by Chen et
al. (46). Altered endocytic environment on the biogenesis of the lysosomes was also demonstrated in the fibroblasts of patient suffering from sialic acid storage disease (47).
The overall results reported in this study demonstrate that the gene
therapy of TS disease could be achieved by a direct gene transfer
strategy. Nevertheless, the therapy of the lysosomal storage disorder
is based on the combination of direct and cross-correction gene
transfer strategies. Indeed, the end point of both approaches is the
production of a functional HexA in the lysosomes. Although direct
transduction was demonstrated to be able to restore the phenotype in
several lysosomal disorders (16, 18, 19, 48-50), the efficacy of the
cross-correction has been shown for very few lysosomal diseases (51,
52). The clarification of the cross-correction mechanism is necessary
for the therapeutic administration of the missing enzyme to patients
and for the distribution of the secreted enzyme by implanted
engineered cells to neighboring deficient cells and across same
non-permeable membranes (e.g. the blood-brain barrier, ependyma).
Here, we provide data exploring this process and showing that the
internalized enzyme probably undergoes a more complex turnover via a
mechanism that is not yet known. Moreover, from our data emerges the
necessity to follow the enzyme topology in the cross-corrected cells by
feeding natural compounds to cells before considering the enzyme
replacement therapy as a potential cure for TS disease and similar
genetic disorders.
 |
ACKNOWLEDGEMENTS |
We thank Prof. L. Naldini, Prof. L. Poenaru,
Dr. A. Trojani, Dr. A. Consiglio, Dr. D. Dolcetta, and M. Leving for
helpful comments and critical reading of the manuscript. We thank the "Laboratorio di Diagnosi Pre/Post-Natale Malattie Metaboliche," Istituto G. Gaslini (Genova, Italy) for providing specimens of patients
affected by genetic disease from the cell lines bank.
 |
FOOTNOTES |
*
This work was supported in part by a grant from Ministero
Italiano della Sanità, progetto di ricerca finalizzata 1999 (coordinator Dr. Bruno Bembi, Pediatric Hospital "Burlo Garofalo,"
Trieste) (to A. O.) and a grant from "Cofinaziamento Ministero
dell'Università e della Ricerca Scientifica e Tecnologica
(MURST) Progetti di Interesse Nazionale (PRIN) 2001" and "Consiglio
Nazionale delle Ricerche (CNR): target project Biotecnology" (to
A. O. and S. S.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
To whom correspondence should be addressed: Dipartimento di Scienze
Biochimiche e Biotecnologie Molecolari, University of Perugia, Via del
Giochetto, 06126 Perugia, Italy. Tel.: 39-075-585-2187; Fax:
39-075-585-2185/7443; E-mail: martino.sabata@hsr.it.
Published, JBC Papers in Press, March 28, 2002, DOI 10.1074/jbc.M106164200
 |
ABBREVIATIONS |
The abbreviations used are:
TS, Tay-Sachs;
HexA,
-hexosaminidase A;
MUG, 4-methylumbelliferyl
-N-acetylglucosaminide;
MUGS, 4-methyumbelliferyl
-N-acetylglucosamine-6-sulfate;
EMEM, Eagle's minimum
essential medium.
 |
REFERENCES |
| 1.
|
Gravel, R. A.,
Kaback, M. M.,
Proia, R. L.,
Sandhoff, K.,
Suzuki, K.,
and Suzuki, K.
(2001)
in
The Metabolic and Molecular Bases of Inherited Disease
(Scriver, C. R.
, Beaudet, A. L.
, Valle, D.
, and Sly, W. S., eds), 8th Ed., Vol. III
, pp. 3827-76, McGraw-Hill Inc., New York
|
| 2.
|
Mahuran, D. J.
(1999)
Biochim. Biophys. Acta
1455,
105-138[Medline]
[Order article via Infotrieve]
|
| 3.
|
Neufeld, E. F.
(1991)
Annu. Rev. Biochem.
60,
57-80
|
| 4.
|
Emiliani, C.,
and Orlacchio, A.
(1992)
Int. J. Biochem.
24,
539-544[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Mahuran, D. J.,
Novak, A.,
and Lowden, J. A.
(1985)
Current Topics in Biological and Medical Research
, Vol. 12
, pp. 229-288, Alan Liss, Inc., New York
|
| 6.
|
Tancini, B.,
Emiliani, C.,
Mencarelli, S.,
Cavalieri, C.,
Stirling, J. L.,
and Orlacchio, A.
(2000)
Biochim. Biophys. Acta
1475,
184-190[Medline]
[Order article via Infotrieve]
|
| 7.
|
Ikonne, J. U.,
Rattazzi, M. C.,
and Desnick, R. J.
(1975)
Am. J. Hum. Genet.
27,
639-650[Medline]
[Order article via Infotrieve]
|
| 8.
|
Hou, Y.,
Tse, R.,
and Mahuran, D. J.
(1996)
Biochemistry
35,
3963-3969[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Emiliani, C.,
Beccari, T.,
Tabilio, A.,
Orlacchio, A.,
Hosseini, R.,
and Stirling, J. L.
(1990)
Biochem. J.
267,
111-117[Medline]
[Order article via Infotrieve]
|
| 10.
|
Emiliani, C.,
Falzetti, F.,
Orlacchio, A,
and Stirling, J. L.
(1990)
Biochem. J.
272,
211-215[Medline]
[Order article via Infotrieve]
|
| 11.
|
Hepbildikler, S. T.,
Sandhoff, R.,
Kolzer, M.,
Proia, R. L.,
and Sandhoff, K.
(2001)
J. Biol. Chem.
277,
2562-2572[Abstract/Free Full Text]
|
| 12.
|
Proia, R. L.,
d'Azzo, A.,
and Neufeld, E. F.
(1984)
J. Biol. Chem.
259,
3350-3354[Abstract/Free Full Text]
|
| 13.
|
Weitz, G.,
and Proia, R. L.
(1992)
J. Biol. Chem.
267,
10039-10044[Abstract/Free Full Text]
|
| 14.
|
Meier, E. M.,
Schwarzmann, G.,
Furst, W.,
and Sandhoff, K.
(1991)
J. Biol. Chem.
66,
1879-1887
|
| 15.
|
Kolter, T.,
Doering, T.,
Wilkening, G.,
Werth, N.,
and Sandhoff, K.
(1999)
Biochem. Soc. Trans.
27,
9-15
|
| 16.
|
Ioannou, Y. A.
(2000)
J. Am. Soc. Nephrol.
11,
1542-1547[Free Full Text]
|
| 17.
|
Barranger, J. A.,
Rice, E. O.,
and Swaney, W. P.
(1999)
Neurochem. Res.
4,
601-615
|
| 18.
|
Eto, Y.,
and Ohashi, T.
(2000)
J. Inherit. Metab. Dis.
23,
293-298[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Poenaru, L.
(1996)
Gene. Ther.
3,
1039-1041[Medline]
[Order article via Infotrieve]
|
| 20.
|
Winchester, B.,
Vellodi, A.,
and Young, E.
(2000)
Biochem. Soc. Trans.
28,
150-154[Medline]
[Order article via Infotrieve]
|
| 21.
|
Consiglio, A.,
Quattrini, A.,
Martino, S.,
Bensadoun, J. C.,
Dolcetta, D.,
Troiani, A.,
Tenaglia, G.,
Marchesini, S.,
Cestari, V.,
Oliverio, A.,
Bordignon, C.,
and Naldini, L.
(2001)
Nat. Med.
7,
310-316[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Wada, R.,
Tifft, C. J.,
and Proia, R. L.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
10954-10959[Abstract/Free Full Text]
|
| 23.
|
Chigorno, V.,
Pitto, M.,
Cardace, G.,
Acquotti, D.,
Kirschner, G.,
and Sonnino, S.
(1985)
Glycoconj. J.
2,
279-291[CrossRef]
|
| 24.
|
Bonini, C.,
Ferrari, G.,
Verzeletti, S.,
Servida, P.,
Zappone, E.,
Ruggirei, L.,
Ponzoni, M.,
Rossigni, S.,
Mavilio, F.,
Traversari, C.,
and Bordignon, C.
(1997)
Science
276,
1719-1724[Abstract/Free Full Text]
|
| 25.
|
Martino, S.,
Emiliani, C.,
Orlacchio, A.,
Hosseini, R.,
and Stirling, J. L.
(1995)
Biochim. Biophys. Acta
1243,
489-495[Medline]
[Order article via Infotrieve]
|
| 26.
|
Tettamanti, G.,
Bonali, F.,
Marchesini, S.,
and Zambotti, V.
(1973)
Biochim. Biophys. Acta
296,
160-170[Medline]
[Order article via Infotrieve]
|
| 27.
|
Acquotti, D.,
Poppe, L.,
Dabrowski, J.,
von der Lieth, G. W.,
Sonnino, S.,
and Tettamanti, G.
(1990)
J. Am. Chem. Soc.
112,
7772-7778[CrossRef]
|
| 28.
|
Brocca, P.,
Acquotti, D.,
and Sonnino, S.
(1993)
Glycoconj. J.
10,
441-446[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Sonnino, S.,
Chigorno, V.,
and Tettamanti, G.
(2000)
Methods Enzymol.
311,
639-656[Medline]
[Order article via Infotrieve]
|
| 30.
|
Sonnino, S.,
Nicolini, M.,
and Chigorno, V.
(1996)
Glycobiology
6,
479-487[Free Full Text]
|
| 31.
|
Hasylik, A.,
von Figura, K.,
Conzelmann, E.,
Nehrkoen, H.,
and Sandhoff, K.
(1982)
Eur. J. Biochem.
125,
317-321[Medline]
[Order article via Infotrieve]
|
| 32.
|
Bradford, M. M.
(1976)
Anal. Biochem.
72,
248-254[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Beccari, T.,
Emiliani, C.,
Hosseini, R.,
Orlacchio, A.,
and Stirling, J. L.
(1987)
Biochem. J.
244,
801-804[Medline]
[Order article via Infotrieve]
|
| 34.
|
Martino, S.,
Emiliani, C.,
Tabilio, A.,
Falzetti, F.,
Stirling, J. L.,
and Orlacchio, A.
(1997)
Biochim. Biophys. Acta
1335,
5-15[Medline]
[Order article via Infotrieve]
|
| 35.
|
Kornfeld, S.
(1992)
Annu. Rev. Biochem.
61,
307-330[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Le Borgne, R.,
and Hoflack, B.
(1998)
Biochim. Biophys. Acta
1404,
195-209[Medline]
[Order article via Infotrieve]
|
| 37.
|
Munier-Lehmann, H.,
Mauxion, F.,
and Hoflack, B.
(1996)
Biochem. Soc. Trans.
24,
33-36
|
| 38.
|
Guidotti, J.,
Akli, S.,
Castelnau-Ptakhine, L.,
Kahn, A.,
and Poenaru, L.
(1998)
Hum. Mol. Genet.
7,
831-838[Abstract/Free Full Text]
|
| 39.
|
Banerjee, P.,
Boyers, M. J.,
Berry-Kravis, E.,
and Dawson, G.
(1994)
J. Biol. Chem.
269,
4819-4826[Abstract/Free Full Text]
|
| 40.
|
Lacorazza, H. D.,
Flax, J. D.,
Snyder, E. Y.,
and Jendoubi, M.
(1996)
Nat. Med.
2,
424-429[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Korneluk, R. G.,
Mahuran, D. J.,
Neote, K.,
Klavins, M. H.,
O'Dowd, B. F.,
Tropak, M.,
Willard, H. F.,
Anderson, M. J.,
Lowden, J. A.,
and Gravel, R. A.
(1986)
J. Biol. Chem.
261,
8407-8413[Abstract/Free Full Text]
|
| 42.
|
Myerowitz, R.,
Piekarz, R.,
Neufeld, E. F.,
Shows, T. B.,
and Suzuki, K.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
7830-7834[Abstract/Free Full Text]
|
| 43.
|
Chen, C. S.,
Patterson, M. C.,
Wheatley, C. L.,
O'Brien, F. J.,
and Pagano, R. E.
(1999)
Lancet
354,
901-905[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Kabayashi, T.,
Stang, E.,
Fang, K. S.,
de Moerloose, P.,
Parton, R. G.,
and Gruenberg, J.
(1998)
Nature
392,
192-197
|
| 45.
|
Pagano, R. E.,
Puri, V.,
Dominguinez, M.,
and Marx, D. L.
(2000)
Traffic
1,
807-815[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Chen, C. S.,
Bach, G.,
and Pagano, R. E.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
6373-6378[Abstract/Free Full Text]
|
| 47.
|
Schmid, J. A.,
Mach, L.,
Paschke, E.,
and Glossl, J.
(1999)
J. Biol. Chem.
274,
19063-19071[Abstract/Free Full Text]
|
| 48.
|
Akli, S.,
Guidotti, J. E.,
Vigne, E.,
Perricaudet, M.,
Sandhoff, K.,
Kahn, A.,
and Poenaru, L.
(1996)
Gene Ther.
9,
769-774
|
| 49.
|
Guidotti, J. E.,
Mignon, A.,
Haase, G.,
Caillaud, C.,
McDonell, N.,
Kahn, A.,
and Poenaru, L.
(1999)
Hum. Mol. Genet.
8,
831-838[Abstract/Free Full Text]
|
| 50.
|
Sena-Esteves, M.,
Camp, S. M.,
Alroy, J.,
Breakefield, X. O.,
and Kaye, E. M.
(2000)
Hum. Gene. Ther.
11,
715-727[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Beutler, E.
(1997)
Curr. Opin. Hematol.
1,
19-23
|
| 52.
|
Brady, R. O.,
and Schiffmann, R.
(2000)
JAMA
284,
2771-2775[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles: